首页|免疫检查点抑制剂相关心肌炎的诊疗进展

免疫检查点抑制剂相关心肌炎的诊疗进展

扫码查看
随着免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肿瘤治疗领域中的广泛应用,其引发的一系列心血管系统的免疫相关不良反应已引起临床重视。ICIs相关心肌炎的发生率虽然较低,但该并发症的高致命性使其成为重点关注对象。目前,关于ICIs诱导心肌炎的分子机制及病理生理过程的认知尚不充分。本文通过文献综述,探索ICIs相关心肌炎的发生机制、危险因素、临床特点、诊断与监测手段以及合理治疗策略的制定,以期提高临床医生对此类不良事件的警觉度与处理能力,从而改善肿瘤患者的预后。
Advances in diagnosis and treatment of myocarditis caused by immune checkpoint inhibitors
With the wide application of immune checkpoint inhibitors(ICIs)in the field of tumor treatment,a series of immune-related adverse reactions of cardiovascular system caused by ICIs have aroused clinicians'attention.ICIs-associated myocarditis has become a focus due to its relatively low incidence but high lethality.At present,we have not known enough about the molecular mechanism and pathophysiological process of ICIs-induced myocarditis.This paper explores the pathological mechanisms of ICIs-associated myocarditis,its risk factors,clinical features,means of diagnosis and monitoring,and formulation of reasonable treatment strategies through literature review,so as to enhance clinicians'alertness and ability to deal with such adverse events,and improve the prognosis of tumor patients.

immune checkpoint inhibitormyocarditiscardiotoxicitycancer immunotherapy

谭梦琴、罗丹、张舟、王福军

展开 >

418000 湖南怀化,湖南医药学院总医院急救医学中心

416000 湖南吉首,湘西土家族苗族自治州人民医院心内科

571100 海南海口,海南省老年病医院心脏中心

免疫检查点抑制剂 心肌炎 心脏毒性 肿瘤免疫治疗

2024

实用心电学杂志
江苏大学

实用心电学杂志

影响因子:0.648
ISSN:2095-9354
年,卷(期):2024.33(6)